INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 41h ago
House PTR1h ago
SEC 13F1h ago
Robinhood Chain1h ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02FWFogarty Patrick W0B / 150S150 trades$600K
  3. 03SPSaba Capital Management, L.P.65B / 19S · 11 late84 trades$21.64M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SJSheena Jonathan0B / 45S45 trades$3.01M
  8. 08SISarowitz Steven I2B / 34S36 trades$22.46M
  9. 09SLSpeiser Michael L0B / 35S35 trades$14.00M
  10. 10RARothblatt Martine A0B / 33S33 trades$5.50M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

72,525 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
12
ML
Mastrocola LaurenPrincipal Accounting Officer
PRAXPraxis Precision Medicines, Inc.
Tax withholding
F$95K
344 sh
Jan 12, 2026
Page 1493 of 1814
← PrevNext →
Jan 13, 2026
traded Jan 12, 2026
+1d
SEC Form 4

Evidence

12
FM
Fong MorganGENERAL COUNSEL & SECRETARY
CARTMaplebear Inc.
Option exercise
M$76K
10.4K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

12
GR
Greathouse Steven RobertSVP & CHIEF INVESTMENT OFFICER
CTOCTO Realty Growth, Inc.
Tax withholding
F$110K
5,981 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

12
HA
Haynes-Gaspar AshleyEVP and Chief Revenue Officer
LUMNLumen Technologies, Inc.
Tax withholding
F$242K
30.6K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

12
SM
Sniecinski MeganChief Operating Officer
PRAXPraxis Precision Medicines, Inc.
Tax withholding
F$244K
885 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

12
LJ
Lee David J.Director, See Remarks
WBTNWEBTOON Entertainment Inc.
Tax withholding
F$142K
10.3K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

12
SE
Smith Daniel EarlSVP, GEN COUNSEL & CORP SECRET
CTOCTO Realty Growth, Inc.
Tax withholding
F$132K
7,174 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

12
NA
Nemiroff AlexGeneral Counsel and Secretary
PRAXPraxis Precision Medicines, Inc.
Tax withholding
F$212K
768 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

12
FH
Fiore Michael HenryEVP, CHIEF COMMERCIAL OFFICER
HQYHEALTHEQUITY, INC.
Tax withholding
F$166K
1,744 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

12
LD
Ladd DelanoEVP, General Counsel
HQYHEALTHEQUITY, INC.
Tax withholding
F$70K
739 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

12
NS
Neeleman StephenDirector, FOUNDER AND VICE CHAIRMAN
HQYHEALTHEQUITY, INC.
Tax withholding
F$75K
791 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

12
MH
Meyer Seth HChief Financial Officer
HTGCHercules Capital, Inc.
Tax withholding
F$75K
4,052 sh
Jan 11, 2026Jan 13, 2026
traded Jan 11, 2026
+2dSEC Form 4

Evidence

12
LM
Lucania James MEVP & CFO
HQYHEALTHEQUITY, INC.
Tax withholding
F$235K
2,470 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

11
BS
Baig SaqibChief Accounting Officer
PTONPELOTON INTERACTIVE, INC.
Open-market sale · 10b5-1 plan
SELL$35K
5,000 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

11
MK
McCarthy Brian K.Pres.,Global Sales & Field Ops
RBRKRubrik, Inc.
Open-market sale · 10b5-1 plan
SELL$140K
2,000 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

11
FM
Francis John Milton IVChief Operating Officer
ROLRHigh Roller Technologies, Inc.
Grant or award
A—
75.0K sh
Jan 8, 2026Jan 13, 2026
traded Jan 8, 2026
+5dSEC Form 4

Evidence

11
CJ
Congleton JonDirector, Chief Executive Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$236K
7,117 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$22K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$22K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$21K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$22K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$43K
80 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$16K
30 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
TC
Thygesen Allan C.Director, President and CEO
DOCUDOCUSIGN, INC.
Open-market sale · 10b5-1 plan
SELL$21K
300 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$43K
80 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
LH
Litinsky James H.Director, Chairman and CEO
MPMP Materials Corp. / DE
Grant or award
A—
65.4K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$22K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$48K
89 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
BZ
Botelho Kiersten ZazaChief Legal Officer & CCO
HTGCHercules Capital, Inc.
Tax withholding
F$15K
822 sh
Jan 11, 2026Jan 13, 2026
traded Jan 11, 2026
+2dSEC Form 4

Evidence

9
TC
Turtle CameronDirector, Chief Executive Officer
SYRESpyre Therapeutics, Inc.
Grant or award
A—
528.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
KD
Kornberg Roger D.Director
COCPCocrystal Pharma, Inc.
Grant or award
A—
24.6K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
NJ
Nisco JamesSVP, Fin/Treas, Chief Actg Off
LSTALISATA THERAPEUTICS, INC.
Grant or award
A—
7,000 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
KJ
Kemly Thomas J.Director, President & CEO
CLBKColumbia Financial, Inc.
Grant or award
A$1,787
117 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
SD
Schneider DavidDirector
ZSZscaler, Inc.
Grant or award
A—
1,076 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

9
BK
Buck Kristen KEVP, R&D and CMO
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$4,230
2,147 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
RD
Reilly DavidDirector
ALLYAlly Financial Inc.
Grant or award
A$33K
718 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
BK
Buck Kristen KEVP, R&D and CMO
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$5,875
2,982 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
IT
Imam TariqSVP, Bus Dev, General Counsel
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$1,011
513 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Grant or award
A—
140.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
TF
Tematio Jean FelixVP, CAO & Corporate Controller
UGIUGI CORP /PA/
Option exercise
M—
2,930 sh
Jan 11, 2026Jan 13, 2026
traded Jan 11, 2026
+2dSEC Form 4

Evidence